Table 1.
Clinical characteristics of NAFLD patients according to the PNPLA3 genotype.
| NAFLD (n = 54) | Wild type (CC carrier) (n = 15) | PNPLA3 (GC/GG variant carrier) (n = 39) | p-value | |
|---|---|---|---|---|
| Age (years) | 48.6 ± 12.4 | 51.7 ± 47.3 | 47.3 ± 12.6 | 0.307 |
| Women (%) | 48.1 | 40.0 | 51.3 | 0.731 |
| Current cigarette smokers (%) | 32.5 | 33.3 | 32.1 | 1.000 |
| Arterial hypertension (%) | 47.5 | 83.3 | 32.1 | <0.05 |
| Diabetes Mellitus (%) | 40.0 | 25.0 | 46.4 | 0.297 |
| Body Mass Index (kg/m2) | 29.3 ± 4.2 | 29.0 ± 3.5 | 29.4 ± 4.5 | 0.785 |
| Waist circumference (cm) | 104.1 ± 10.3 | 103.7 ± 9.9 | 104.2 ± 10.7 | 0.889 |
| Metabolic syndrome (%) | 59.0 | 60.0 | 59.0 | 0.598 |
| Fasting plasma glucose (mg/dl) | 105.9 ± 36.4 | 96.7 ± 16.5 | 110.1 ± 42.2 | 0.295 |
| Total cholesterol (mg/dl) | 195.3 ± 36.8 | 189.9 ± 38.7 | 197.6 ± 36.6 | 0.569 |
| Low density lipoprotein (mg/dl) | 116.1 ± 30.6 | 111.4 ± 40.9 | 117.9 ± 26.4 | 0.574 |
| High density lipoprotein (mg/dl) | 48.5 ± 22.8 | 43.0 ± 9.0 | 50.7 ± 26.3 | 0.350 |
| Triglycerides (mg/dl) | 157.4 ± 103.0 | 163.2 ± 72.8 | 155.1 ± 114.1 | 0.830 |
| Statin (%) | 19.4 | 16.7 | 20.8 | 1.000 |
| Aspartate aminotransferase (U/l) | 49.9 ± 33.1 | 39.2 ± 17.7 | 54.4 ± 37.2 | 0.089 |
| Alanine aminotransferase (U/l) | 82.2 ± 48.2 | 62.2 ± 32.9 | 90.8 ± 51.6 | <0.05 |
| GGT (U/l) | 71.4 ± 57.0 | 74.2 ± 79.7 | 70.2 ± 46.0 | 0.845 |
| Creatinine (mg/dl) | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.699 |
| sNox2-dp (pg/ml) | 37.2 ± 15.0 | 33.8 ± 10.3 | 38.7 ± 16.6 | 0.270 |
| Serum F2-Isoprostanes (pg/ml) | 70.1 ± 11.7 | 64.4 ± 14.8 | 72.5 ± 9.4 | <0.05 |
Data are reported as mean ± standard deviation. p value in bold are statistically significant. NAFLD: nonalcoholic fatty liver disease; PNPLA3: patatin-like phospholipase domain containing 3; GGT: Gamma-glutamyltranspeptidase; sNox2-dp: soluble Nox2-derived peptide.